Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability

Journal of Infectious Diseases

Volumn 206, Issue 6, 2012, Pages 860-866

  Leval, Amy ^a   Herweijer, Eva ^a   Arnheim Dahlström, Lisen ^a   Walum, Hasse ^a   Frans, Emma ^a   Sparén, Pär ^a   Simard, Julia F ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; CONDYLOMA ACUMINATUM; DISEASE REGISTRY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; SCHOOL CHILD; SEX DIFFERENCE; SWEDEN; TREND STUDY; VACCINATION;

ADOLESCENT; ADULT; AGE DISTRIBUTION; CHILD; CONDYLOMATA ACUMINATA; FEMALE; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRUS VACCINES; SWEDEN; TIME FACTORS; YOUNG ADULT;

EID: 84865711912     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis405     Document Type: Article

References (28)

1. Kjaer SK, Tran TN, Sparen P. The burden of genital warts. A study of nearly 70,000 women from the general female population in four Nordic countries. J Infect Dis 2008; 196:1447-54.
2. Persson G, Andersson K, Krantz I. Symptomatic genital papillomavirus infection in a community. Acta Obstet Gynecol Scand 1996; 75:287-90.
3. Wang H, Qiao YL. Human papillomavirus type-distribution in condylomata acuminata of mainland China: a meta-analysis. Int J STD AIDS 2008; 19:680-4.
4. FUTURE I/II Study Group; Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 340:c3493.
5. Gilbert P, Brewer N, Reiter P, Ng T, Smith J. HPV vaccine acceptability in heterosexual, gay, and bisexual men. Am J Mens Health 2011; 5:297-305.
6. Dahlström LA, Sundström K, Young C, Lundholm C, Sparen P, Tran TN. Awareness and knowledge of human papillomavirus in the Swedish adult population. J Adolesc Health 2012; 50:204-6.
7. Tegnell A, Dillner J, Andrae B. Introduction of human papillomavirus (HPV) vaccination in Sweden. Euro Surveill 2009; 14:pii 19119.
8. Ludvigsson J, Andersson E, Ekbom E, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011; 11:450.
9. Ludvigsson J, Otterblad-Olausson P, Pettersson B, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24:659-67.
10. Lacey CJN, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24(Supplement 3):S35-41.
11. (LIF), S.A.o.t.P.I. and S.A.o.L.A.a.R. (SKL). FASS, the Swedish Medicines Compendium for physicians. Stockholm, Sweden: Swedish Association of the Pharmaceutical Industry, LIF; 2011.
12. Mayeaux EJ, Dunton C. Modern management of external genital warts. J Low Genit Tract Dis 2008; 12:185-92.
13. Eklind J, Tartler U, Maschke J, Lidbrink P, Hengge U. Imiquimod to treat different cancers of the epidermis. Dermatol Surg 2003; 29:890-6.
14. Donovan B, Franklin N, Guy R, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11:39-44.
15. Fairley CK, Hocking J, Gurrin L, Chen M, Donavan B, Bradshaw C. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85:499-502.
16. Read TRH, Hocking J, Chen M, Donavan B, Bradshaw C, Fairley C. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87:544-7.
17. Soldan K, Howell-Jones R, Leong G, Hughes G, Gill O. Is HPV 16/18 immunisation causing declines in genital warts in England? 2011 International Papillomavirus Conference; Sept. 17-22; 2011; Berlin, Germany [ place unknown, publisher unknown]; 2011.
18. Tyden T, Palmqvist M, Larsson M. A repeated survey of sexual behavior among female university students in Sweden. Acta Obstet Gynecol Scand 2011; 91:215-0.
19. Herlitz C. Sexual risk-taking in the general population of Sweden (1989-2007). Sex Health 2009; 6:272-80.
20. Velicko I, Unemo M. Increase in reported gonorrhoea cases in Sweden, 2001-2008. Euro Surveill 2009; 14:pii 19315.
21. Kraut A, Schink T, Schulze-Rath R, Mikolajczyk R, Garbe E. Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis 2010; 10:360.
22. Desai S, et al. Genital warts and cost of care in England. Sex Transm Infect 2011; 87:464-8.
23. Koshiol JE, Laurent SA, Pimenta JM. Rate and predictors of new genital warts claims and genital warts-related healthcare utilization among privately insured patients in the United States. Sex Transm Dis 2004; 31:748-52.
24. Trottier H, Mahmud S, Prado J, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008; 197:1436-47.
25. Castle PE, Zhao F-H. Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programs. J Infect Dis 2011; 204:335-7.
26. Hammarlund K, Nystrom M. The lived experience of genital warts: the Swedish example. Health Care Women Int 2004; 25:489-502.
27. Nordenvall C, Change E, Adami HO, Ye W. Cancer risk among patients with condylomata acuminata. Int J Cancer 2006; 119:888-93.
28. Trottier H, Ferreira S, Thomann P, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 2010; 70:8569-77.